Aurinia Pharmaceuticals Inc.
AUPHDrugs in Pipeline
7
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Jul 30, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
AUPH Earnings Report
EPS Est: $0.18 | FQ end 2026-06
How AUPH's past catalysts played out
Ciclosporin
Psoriasis
Voclosporin
Lupus Nephritis
0.05% Voclosporin Ophthalmic Solution (VOS)
Dry Eye Syndrome
Aritinercept
Myasthenia Gravis, Generalized
tacrolimus
Kidney Diseases
Voclosporin High Dose
Lupus Nephritis
Voclosporin Ophthalmic Solution
Dry Eye
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ciclosporin | Phase 3 | Psoriasis | - | - |
Voclosporin | Phase 3 | Lupus Nephritis | - | - |
0.05% Voclosporin Ophthalmic Solution (VOS) | Phase 3 | Dry Eye Syndrome | - | - |
Aritinercept | Phase 2 | Myasthenia Gravis, Generalized | - | - |
tacrolimus | Phase 2 | Kidney Diseases | - | - |
Voclosporin High Dose | Phase 2 | Lupus Nephritis | - | - |
Voclosporin Ophthalmic Solution | Phase 2 | Dry Eye | - | - |
Lupus Nephritis
3 drugs in this indication
Psoriasis
2 drugs in this indication
Kidney Diseases
1 drug in this indication
Dry Eye Syndrome
1 drug in this indication
Dry Eye
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Aurinia Pharmaceuticals Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Aurinia Pharmaceuticals Inc.'s (AUPH) pipeline across Phase 3, Phase 2. Its lead program is Ciclosporin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aurinia Pharmaceuticals Inc.'s next FDA catalyst?→
Aurinia Pharmaceuticals Inc.'s (AUPH) next tracked catalyst is a Earnings expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AUPH biotech catalysts?→
Add AUPH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aurinia Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.